Kailera Therapeutics closes IPO raising $718.8M; issues 44.9M shares at $16.00

Kailera Therapeutics, Inc.

Closed IPO of 44,921,875 shares at $16.00 per share, including full exercise of underwriters' option for 5,859,375 additional shares.
Gross proceeds of $718.8 million before underwriting discounts and offering expenses.
Amended certificate of incorporation: authorized 800M shares of common stock and 10M shares of undesignated preferred stock.
Adopted classified board with staggered three-year terms; directors removable only for cause with two-thirds vote.
Amended bylaws to require advance notice for stockholder proposals and director nominations, and limit action by written consent.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kailera Therapeutics, Inc.: Amended and restated certificate of incorporation to fix authorized common stock, authorize undesignated preferred stock, establish classified board with staggered terms, require cause for director removal, require advance notice, eliminate written consent, and designate exclusive forums (effective 2026-04-20).

Change: charter amendment
Effective: 2026-04-20

Exact text from the filing

On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kailera Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations and conform to charter amendments (effective 2026-04-20).

Change: bylaw amendment
Effective: 2026-04-20

Exact text from the filing

On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors, became effective.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Kailera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-164040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.